Latest Signals

Recovered sponsor decision and newly posted registry status. Novartis ended the pelacarsen ASCVD program in an October 16 patient letter; the November 10 registry now records its safety extension as terminated. This is separate from the November 7 numerical efficacy report. Original Novartis patient-community statement, October 16, 2026; fhef.org · news release; ClinicalTrials.gov: pelacarsen open-label extension, update November 10, 2026; full notes.

Newly posted registry recruitment milestone; no outcomes. VERVE-102’s randomized Phase 2 HEART-3 trial now lists recruiting and an actual September 24 start. LDL lowering and long-term safety remain to be established in this trial. ClinicalTrials.gov — HEART-3 first posted September 24, 2026; full notes.

New trial-registry protocol; no results. A newly registered oral-ecnoglutide trial will measure 24-week weight change in Chinese adults; the oral formulation is separate from injectable ecnoglutide evidence. ClinicalTrials.gov · NCT07929298; full notes.

New randomized screening-delivery protocol; no results. A new 852-person study will compare mailed FIT/HPV self-sampling with usual practice, measuring completion and diagnostic resolution rather than test accuracy or mortality. ClinicalTrials.gov · NCT07927686; full notes.

Registry recruitment update and sponsor CTAD program; no efficacy readout. Roche identifies RG6434 as the NLRP3 inhibitor in TARBELA-AD (RO7568282). The 450-person Phase 2 registry now lists recruitment, with 72-week cognitive/function outcomes planned. CTAD will separately cover early safety, trontinemab biomarkers, prevention-trial design and diagnostics. roche.com · source page; gene.com · news release; ClinicalTrials.gov · NCT07781657; full notes.

Sponsor-reported randomized Phase 3 result presented at NEI; full poster unappraised. At three weeks, Study 452 reports a 3.7-point greater mania-score reduction with lumateperone than placebo; 43.9% versus 23.7% had at least a 50% symptom-score reduction. J&J plans a U.S. submission, and acute mania remains unapproved. jnj.com · news release; ClinicalTrials.gov · NCT06462612; full notes.

New randomized Phase 2 registry protocol; no outcomes. RENEW-MDD-3 will test the dual GIP/GLP-1 agonist brenipatide versus placebo alongside a stable antidepressant in 330 adults. The primary endpoint is depression symptoms at week 10; recruitment and benefit are not yet established. ClinicalTrials.gov · NCT07928245; lilly.com · source page; full notes.

Sponsor access/status update and forecasts; no new efficacy readout. The sponsor confirms first commercial Isembyld infusions in October and forecasts Q1 2027 public SRK-439 data, distinct from having topline data by year-end 2026. investors.scholarrock.com · news release; sec.gov · source page; full notes.

Original Phase 3 conference abstracts newly appraised; earlier toplines/publication already known. ACR abstracts quantify WOMAC pain changes in TRIUMPH-4 and the 574-person TRIUMPH-1-OA substudy, preserving efficacy estimands. These are symptom/function findings, not cartilage repair. Retatrutide for knee osteoarthritis pain and obesity, 68-week TRIUMPH-4 Phase 3 ACR abstract; Retatrutide for knee osteoarthritis and obesity, 80-week TRIUMPH-1-OA Phase 3 ACR abstract; PubMed · PMID 42814954; full notes.

Original conference abstract newly appraised; previously announced efficacy, exploratory week 52. TOGETHER-PsA’s original abstract adds analysis-arm counts of 138/133 and an ACR50 difference of 28.0 percentage points (95% CI 17.1–38.9). Week 52 remains exploratory; matched numeric harms remain missing. acrabstracts.org · source page; full notes.

New randomized Phase 4 pilot protocol; no results. A 40-person open-label knee-replacement trial adds suzetrigine to multimodal care. Primary endpoints concern feasibility; opioid use and pain are separate outcomes. ClinicalTrials.gov · NCT07928011; full notes.

Sponsor-only long-term antibody follow-up; historical FDA safety and access context. Valneva reports a 94% five-year antibody response in 221 evaluable adults. This does not establish clinical efficacy; the live vaccine’s earlier U.S. safety suspension and discontinuation remain distinct. GlobeNewswire · news release; valneva.com · news release; FDA · regulatory information; full notes.

Sponsor safety/development update. Syntara paused Phase 1b SNT-9465 recruitment after blinded reports of mild-to-moderate skin irritation. Counts and treatment assignment are undisclosed. Unblinded review is expected Q4 2026 before restart or discontinuation; the prior Q1 2027 topline forecast is conditional. newswire.iguana2.com · PDF document; anzctr.org.au · source page; full notes.

New randomized Phase 2 registry protocol; no results. New GR2301 anti-IL-15 Phase 2 registry plans 120 participants, three dose groups and placebo, with week 24 F-VASI50 primary. Not yet recruiting; November 2026 start and May 2028 primary completion estimated. No efficacy, safety or U.S. approval established. ClinicalTrials.gov · NCT07930039; full notes.

Original randomized Phase 2b registry result tables. In a 146-person CKD trial, retatrutide did not improve the 24-week measured-GFR primary comparison. A smaller albuminuria analysis favored treatment; neither establishes prevention of kidney failure. ClinicalTrials.gov · NCT05936151; sponsor trial identity; full notes.

Sponsor-reported enrollment milestone and forecasts. Maze reports over 50 enrolled in the Phase 2 MZE829 HORIZON study in APOL1-mediated kidney disease, with data forecast for early 2027. This is unrelated to pelacarsen’s HORIZON trial. ir.mazetx.com · news release; full notes.

New randomized protocol; no clinical-event result. A type 1 diabetes study plans CGM outcomes at 16 weeks and CCTA plaque measures at 52 weeks. The title’s cardiovascular-protection wording is not evidence of fewer heart attacks. ClinicalTrials.gov · NCT07924553; full notes.

Laboratory-partner enrollment announcement; no clinical-outcome results. GeneDx reports Oregon enrollment activity in the multi-state newborn-genomic-screening study. Enrollment and feasibility remain separate from demonstrated long-term benefit. ir.genedx.com · source document; health.state.mn.us · source page; full notes.

Sponsor-only uncontrolled Phase 2 topline. The PIK-201 report shows responses in selected previously treated endometrial cancers, but has no randomized comparator and reports grade 3-or-higher treatment-related harms in 64%. investors.faeththerapeutics.com · source document; ClinicalTrials.gov · NCT06463028; full notes.

New trial-registry protocols; no outcomes. New SYS6010/enlonstobart studies address postoperative recurrence and recurrent/metastatic disease in distinct cancer populations, with no clinical results yet. ClinicalTrials.gov · NCT07924111; ClinicalTrials.gov · NCT07925021; full notes.

Sponsor-reported completed U.S. submission; regulatory decision pending. Compass says the final COMP360 NDA for treatment-resistant depression is submitted, fulfilling its November 3 forecast. FDA filing acceptance, a product-specific decision date, approval and access are separate and unverified. Compass completes the COMP360 psilocybin NDA for treatment-resistant depression; FDA · regulatory information; full notes.

Sponsor-only exploratory Phase 2a report; uncontrolled five-person study. Definium describes exploratory functional and social measures after one dose of R(-)-MDMA in five autistic adults. The open-label pilot cannot establish efficacy; a multiple-dosing study is forecast for 2027. ir.definiumtx.com · news release; full notes.

New randomized Phase 2/3 trial protocol; no results. A 300-person trial will compare two strengths of daily bevemipretide eye drops with vehicle in extrafoveal geographic atrophy. Its primary outcome is structural photoreceptor loss, not proven vision preservation. ClinicalTrials.gov · NCT07927010; full notes.

DEA interim final rule on public inspection; publication and effective date pending. The DEA rule was filed November 9 and is scheduled to publish and take effect November 12. It puts Orzeyful in Schedule IV. This is a U.S. access milestone after August approval for adult narcolepsy type 1, not confirmation of pharmacy supply or insurer coverage. DEA oveporexton Schedule IV interim final rule, filed November 9, 2026; scheduled publication November 12; takeda.com · source page; full notes.

Dated sponsor conference announcement; no new numerical result. Veru schedules a November 16 post-hoc QUALITY physical-function analysis in adults aged 65 or older; no new effect size or harms table is disclosed. ir.verupharma.com · news release; full notes.

New randomized supportive-care protocol; no results. A new 94-person randomized trial will test exercise plus protein during semaglutide/tirzepatide treatment, measuring MRI muscle volume separately from strength and function. ClinicalTrials.gov · NCT07926152; full notes.

New randomized Phase 2 protocol; no results. PRECISION plans 60 patients and separates CT-defined bone healing from pain, function and return to work; no clinical benefit is established. ClinicalTrials.gov · NCT07924722; full notes.

Sponsor-reported preliminary uncontrolled Phase 1 data. ALLO-329 reports skin-score responses in 8/10 selected scleroderma patients; safety includes serious treatment-emergent events in 6/18. Small nonrandomized conditioning cohorts cannot establish cure or a safety advantage. ir.allogene.com · news release; ClinicalTrials.gov · NCT07085104; full notes.

Sponsor-reported preliminary uncontrolled Phase 1/2 CAR-NK results. NKX019 shows early disease-specific responses in small high-dose subsets. Pooled 40-person safety and limited follow-up do not establish comparative safety or durable remission. sec.gov · source page; ClinicalTrials.gov · NCT06733935; ClinicalTrials.gov · NCT06557265; full notes.

Peer-reviewed single-arm Phase 2 primary analysis; same cohort, earlier cutoff. The KYSA-8 paper adds a 16-week walking-time confidence interval and detailed CRS, ICANS, neutropenia and serious-event descriptions. This is the same 26-person cohort, not independent replication. JAMA Network · article; ClinicalTrials.gov · NCT06588491; full notes.

Sponsor-reported randomized Phase 2 topline. Alenura’s 153-person Phase 2 sponsor report claims superiority over placebo and each component for 12-hour acute bladder-pain relief; effect sizes, confidence intervals and comparative harms remain undisclosed. vaneltix.com · source page; ClinicalTrials.gov · NCT05737121; full notes.

Sponsor-only Phase 2 topline; effect magnitude undisclosed. Valneva reports success on a Phase 2 adult Shigella challenge endpoint without effect magnitude or detailed harms. Separate infant antibody findings do not demonstrate protection. GlobeNewswire · news release; valneva.com · PDF document; ClinicalTrials.gov · NCT06615375; full notes.

Sponsor-reported Phase 2/3 extension results. Sponsor-reported month-12 gains were 29.7/43.9 non-vellus hairs/cm² for continuing once-/twice-daily groups; improved/much-improved patient ratings were 48.4%/68.0%. The 421-person extension includes placebo crossover, leaving no continuing month-12 placebo and no standard-minoxidil head-to-head. Outcome-specific observed-data denominators remain incomplete. ir.veradermics.com · source document; VDPHL01 Study 302 registry — NCT06724614; full notes.

Sponsor numerical account with simultaneous paper publication; full paper not appraised. A small first-human CIDEB-siRNA report shows durable liver-fat reductions, with no proof yet of fibrosis reversal or fewer clinical liver events. investor.regeneron.com · news release; ClinicalTrials.gov · NCT06836609; ClinicalTrials.gov · NCT07854782; full notes.

Sponsor-only randomized open-label Phase 3 topline and conference report. ECLIPSE 1 reports 44% versus 0% viral/liver-lab composite response, comparing active week 48 with delayed-treatment week 12. This is a Phase 3 sponsor topline, not a cure or clinical-outcome result. investors.vir.bio · news release; ClinicalTrials.gov · NCT06903338; full notes.

Sponsor-only Phase 2 extension and exploratory nonrandomized withdrawal snapshot. SOLSTICE reports viral suppression in all 28 week-96 completers and early off-treatment results in 10 selected patients. Unequal follow-up and incomplete flare assessment preclude a cure claim. investors.vir.bio · news release; ClinicalTrials.gov · NCT05461170; full notes.

Sponsor conference reporting; open-label Phase 4 cohorts. Sponsor-reported GLP-1 cohorts improved FACE-Q facial satisfaction by 42.4 points (HARMONY, 30 participants) and 39.6 points (HALO interim 25/75). Open-label single-arm design, short follow-up and incomplete harms prevent claims of comparative benefit or biological fat regeneration. AbbVie · source page; full notes.

Fuller Phase 3 numerical reporting; the negative topline was already known. In adults with established cardiovascular disease and high Lp(a), monthly pelacarsen produced a 77.7% placebo-adjusted Lp(a) reduction at 12 months, but the cardiovascular composite had HR 1.02 (95% CI 0.90–1.15). Adverse events leading to drug discontinuation were 20.6% versus 7.5%. This result concerns this regimen in secondary prevention; exact denominators and the full manuscript tables remain appraisal gaps. Investigator report; AHA report; full notes.

Official conference numerical report; July negative result already saved. ZEUS’s fuller report confirms that lower inflammatory markers did not establish fewer cardiovascular events in adults with ASCVD and CKD; the July HR was already public. newsroom.heart.org · news release; novonordisk.com · source page; full notes.

New randomized Phase 2 registry protocol; no results. A new disease-specific bimagrumab study will test symptoms and walking function separately from lean tissue; recruitment and results remain pending. ClinicalTrials.gov · NCT07920887; full notes.

Registry recruitment milestone; no new efficacy result. ENHANCE-3 is now recruiting with an actual November 2 start; clinical outcomes remain pending. ClinicalTrials.gov · NCT07874815; full notes.

New randomized Phase 2/3 pivotal protocol; no results. A large newly registered maternal-vaccine trial tracks infant antibody thresholds and pregnancy/infant safety, rather than already demonstrating fewer GBS infections. ClinicalTrials.gov · NCT07922226; full notes.

New trial-registry protocol. SELENE-Asia adds a regional Phase 3 lenbelintide protocol, with no new efficacy results. ClinicalTrials.gov; full notes.

New trial-registry protocol. Oral UBT48128 adds a first-human safety and pharmacokinetic program, without demonstrated chronic weight-loss efficacy. ClinicalTrials.gov; full notes.

New trial-registry protocol. A newly registered 1,200-person trial will test dapagliflozin and oral semaglutide on physical function over three years, with actual recruitment unresolved. ClinicalTrials.gov; full notes.

Sponsor-reported China clinical-trial authorization and development forecasts. Sponsor reports clearance for a small China PK/safety study; December enrollment and Q2 2027 completion/data remain forecasts. CBL-514 gains sponsor-reported China trial clearance; full notes.

Peer-reviewed randomized open-label waitlist comparison; primary abstract appraised. In 20 adults with social anxiety disorder, MDMA-assisted therapy improved the week-16 Liebowitz score versus waitlist by 43.3 points (95% CI 29.5–57.1 in favor of treatment). The comparison cannot isolate the drug from therapy and expectancy. PubMed · PMID 42994762; ClinicalTrials.gov · NCT05138068; full notes.

Newly recovered November 6 Phase 3 recruitment update; no results. The VESPER-OSA2 registry now lists recruitment and an actual October 19 start for the non-PAP cohort with overweight or obesity. Its 52-week apnea index endpoint is not evidence of a cardiovascular benefit or PAP replacement. ClinicalTrials.gov · NCT07881757; full notes.

New exploratory registry protocol; no results. A not-yet-recruiting four-person split-face pilot proposes testing whether trenibotE shortens onabotulinumtoxinA effects. No outcomes; design placeholders and incompatible estimated start/completion dates prevent a reliable readout forecast or reversal claim. ClinicalTrials.gov · NCT07923448; full notes.

New randomized procedure/device registration; no results. A new small ankle-cartilage trial compares a scaffold plus microfracture with microfracture alone, with separate imaging and function assessments. ClinicalTrials.gov · NCT07917806; full notes.

Dated sponsor conference announcement; scheduled presentations. Upcoming retatrutide reports address knee pain and function; they should not be read as cartilage-regeneration evidence. Lilly · news release; full notes.

Original randomized Phase 2 registry results; later detailed posting. New detailed Sjogren tables distinguish the higher-dose disease-activity signal, 90% intervals and safety denominators from the lower-dose null result. ClinicalTrials.gov · NCT04968912; full notes.

New open-label early Phase 1 protocol, with limited conference context. A newly registered early GT802 study adds an in-vivo dual-target CAR-T approach, with efficacy and safety still unproven. ClinicalTrials.gov · NCT07917923; full notes.

Sponsor conference preview; exploratory randomized-trial follow-up. An exploratory one-year combination result favors better arthritis response, with denominators, intervals and full comparative harms still needed. Lilly · news release; full notes.

Sponsor-only randomized Phase 2a challenge-study topline. A 50-person asthma challenge trial reports antiviral activity and numerical symptom signals; real-world clinical benefit and repeated-dose safety remain unproven. GlobeNewswire · news release; full notes.

WHO planned-trial expansion and new Phase 1 registry protocol. WHO proposes Bundibugyo-specific candidates for outbreak testing; a separate new age-expansion protocol measures early safety and immune responses. who.int · news release; full notes.

New randomized placebo-controlled Phase 1 protocol. A new early Marburg-vaccine study tests safety and immune responses, with actual enrollment and clinical protection unconfirmed. ClinicalTrials.gov · NCT07919210; full notes.

New trial-registry protocol. BGM1812 adds a 160-person obesity Phase 2 plan with unresolved schedule details. ClinicalTrials.gov; full notes.

Sponsor-reported observational conference analyses. New observational Rezdiffra reports show liver-stiffness changes and treatment persistence, without proving fewer clinical liver events. Primary source; full notes.

New trial-registry protocol. A 1,408-person Phase 3 protocol will compare CagriSema and its components on blood pressure, rather than clinical events. ClinicalTrials.gov; full notes.

New trial-registry protocol. TARGET-CHD compares two inflammation targets after PCI. ClinicalTrials.gov; full notes.

New trial-registry protocol. A newly registered short Phase 2 insomnia study will assess SOM001 safety, sleep onset and sleep maintenance; drug identities remain coded. ClinicalTrials.gov; full notes.

Peer-reviewed observational human study. A large transplant cohort found no adjusted survival-age advantage with mTOR inhibition; healthier-adult intermittent dosing remains a separate unanswered question. Primary source; full notes.

New original registry result tables for a previously stopped randomized Phase 2 trial. AuTonomy posts detailed negative clinical and safety results for posdinemab. ClinicalTrials.gov NCT04619420; full notes.

New trial-registry protocol; no results. Johns Hopkins registers psilocybin plus visual training for adult amblyopia. ClinicalTrials.gov NCT07920081; full notes.

New trial-registry protocol; no results. STATRS will compare medication optimization and seizure-based therapies for resistant schizophrenia. ClinicalTrials.gov NCT07918222; full notes.

FDA accelerated approval, supported by uncontrolled human tumor-response data. FDA grants accelerated approval to Rybrevant Faspro for selected previously treated head-and-neck cancers. FDA indication and efficacy review; full notes.

Sponsor human-study dosing milestone; no new efficacy data. OPGx-BEST1 completes higher-dose cohort and sets a new early 2027 data window. Original November 5 sponsor announcement; full notes.

Peer-reviewed prospective human genomic-screening pilot. A Korean newborn-genome pilot finds actionable conditions missed by usual screening. Full prospective SNUseq Baby paper; full notes.

Dated sponsor/SEC development forecast; older early-human context labeled baseline. Phase 1 IL-2 fusion protein HCW9302 now targets recommended-dose selection in Q1 2027; tiny uncontrolled older responses remain preliminary. sec.gov · source page; full notes.

New original post-approval study registration, with FDA approval history verified. New 45-person U.S. post-approval protocol will study saypha ChIQ safety in Fitzpatrick V/VI skin; no outcomes yet. ClinicalTrials.gov · NCT07918443; full notes.

New combined Phase 2b/3 randomized trial-program registration; not recruiting. New 1,020-participant combined Phase 2b/3 anti-IL-15 program will test facial/body repigmentation; recruitment and numerical dosing remain unverified. ClinicalTrials.gov · NCT07920211; full notes.

Newly posted original registry results of an older terminated Phase 2 study. New registry disclosure concerns a six-person 2019 uncontrolled study halted for reformulation; planned randomized testing did not occur. ClinicalTrials.gov · NCT03756389; full notes.

Newly recovered November 5 Phase 3 registry update; no efficacy readout. The adult daridorexant daytime-function study now records recruitment and an October 28 actual start. Sleep-diary total sleep time is primary; daytime function is secondary. No new U.S. label claim is established. DARI-DREAM primary registry, updated November 5, 2026; Idorsia DARI-DREAM enrollment announcement, October 27, 2026; full notes.

Sponsor-only Phase 1 interim biomarker and safety update. PBGENE-HBV reports undetectable pgRNA in 11/12 evaluable patients and paired biopsies in two. The Phase 1 biomarker findings do not establish cure or long-term safety. precisionbiosciences.gcs-web.com · source page; businesswire.com · news release; ClinicalTrials.gov · NCT06680232; full notes.

Peer-reviewed randomized study; full paper appraised. A 446-person randomized hyamax injection study favored treatment on a short-term composite appearance response versus no intervention (84.9% vs 14.1%). Unblinded participants, no procedure control, more overall adverse events and limited comparative follow-up constrain interpretation. Springer · article; full notes.

Peer-reviewed randomized trial; original abstract appraised. A 40-person sham-controlled laser trial found no root-resorption protection or faster alignment (123.8 vs 126.2 days), despite short-term pain improvement. Two tooth/time comparisons favored sham for resorption; small sample and multiple comparisons limit harm inference. Full paper and harms remain gaps. PubMed · PMID 42988646; DOI · 10.1016/j.ejwf.2026.08.003; full notes.

Sponsor development plan; no numerical efficacy or safety results. The existing neuropathy development plan now names an unspecified novel asset; the earlier sponsor-reported Phase 2 pain signal remains separate. Primary source; full notes.

New randomized open-label Phase 1 pharmacokinetic protocol. A new human-stage NaV1.8 program is testing drug interactions before patient analgesic efficacy is established. ClinicalTrials.gov · NCT07915947; full notes.

New randomized masked Phase 2 protocol; no results. A newly registered combination program targets COPD exacerbations on top of triple inhaled therapy, without results yet. ClinicalTrials.gov · NCT07915791; full notes.

New trial-registry protocol. A newly registered Phase 1 study adds LY4247147 as an early obesity-program lead without a disclosed receptor target. ClinicalTrials.gov; full notes.

Sponsor pipeline disclosure plus original trial registry. Novo adds sourced forecasts for oral zenagamtide, lower-dose oral semaglutide, amylin 355 and CagriSema switching research. Primary source; full notes.

Trial-registry results first posted. New CLARION-CKD tables show no significant blood-pressure advantage for KBP-5074 and more nonserious hyperkalaemia. ClinicalTrials.gov; full notes.

Sponsor development/status clarification. Novo clarifies stopped heart-failure treatment and H1 2027 reporting plans for distinct ziltivekimab studies. Primary source; full notes.

Sponsor development disclosure and original registry; earlier initiation kept dated. Novo reports AMBIENCE initiation, but its older registry still says not yet recruiting after an elapsed estimated start. Primary source; full notes.

Sponsor development statement; accompanying full video unappraised. Avecho forecasts end-2027 completion of a pharmaceutical CBD insomnia program; interim continuation is not proven efficacy. Primary source; full notes.

Sponsor regulatory-timing forecast. GRAIL now forecasts a Galleri FDA decision in early Q1 2027. GRAIL November 4 quarterly release; full notes.

New trial-registry protocol; no results. A new MCED study will test sensitivity in asymptomatic cancer and precancer cases. ClinicalTrials.gov NCT07915271; full notes.

New trial-registry protocol; no results. LungScreen-NEMO will study CT screening in selected never-smokers. ClinicalTrials.gov NCT07914881; full notes.

Sponsor/conference dataset announcement; uncontrolled Phase 2 human evidence. SLS009 combination data add an early signal after venetoclax-resistant AML. Original sponsor November 4 ASH disclosure; full notes.

New registry status disclosure with historical actual dates; no results. AC102’s registry now confirms completed sudden-hearing-loss study; results remain unpublished. ClinicalTrials.gov NCT05776459; full notes.

New randomized Phase 2 registration; no results. New 75-person Phase 2 protocol compares two rhPDGF-BB doses with saline for under-eye hollowing; recruitment and results remain future. ClinicalTrials.gov · NCT07914816; full notes.

New retrospectively registered randomized Phase 4 protocol; no results. New 158-person acne protocol compares two antibiotics on the same tretinoin background; no benefit, harms or resistance results yet. ClinicalTrials.gov · NCT07915648; full notes.

Newly recovered November 4 sponsor-reported FDA designation; not approval. Idorsia says FDA granted Breakthrough Therapy Designation for insomnia ages 10 to under 18. The previously reported short Phase 2 evidence is unchanged; pediatric Phase 3 remains forecast for H2 2027. Idorsia pediatric daridorexant Breakthrough Therapy Designation announcement, November 4, 2026; ClinicalTrials.gov NCT05423717; full notes.

Peer-reviewed randomized study; full paper appraised. Specific Novapath temple PLLA improved blinded six-month appearance ratings versus no treatment (80.2% vs 1.8%; 162 randomized). Local reactions were frequent; controls crossed after six months. It does not establish superiority to other fillers, native fat restoration or long-term comparative durability. Springer · article; full notes.

Sponsor regulatory-submission forecast. Compass narrows its final COMP360 submission window to the next two weeks. Original November 3 sponsor update; full notes.

New trial-registry protocol; no results. A new HS-10380 Phase 3 protocol will test acute schizophrenia symptoms. ClinicalTrials.gov NCT07911787; full notes.

Peer-reviewed Phase 1b human study; small selected efficacy population. A full small randomized-cohort paper shows fewer bloodstream infections, with substantial imprecision and selected-population limits. Nature · article; full notes.

Investigator report of observational human study; full paper pending appraisal. An observational surgery cohort reports weight loss after limited medication response; selection and confounding prevent randomized treatment comparisons. newsroom.clevelandclinic.org · source page; full notes.

New trial registration; no human result. A new Lp(a) program specifies twice-yearly dosing and biomarker outcomes, without cardiovascular-event evidence. ClinicalTrials.gov · NCT07914660; full notes.

Source posting date unknown; checked November 3. Official conference program; original posting date undated, verified November 3. The official AHA program schedules HORIZON and ZEUS reports for November 7; presentation titles do not supply results. professional.heart.org · source page; full notes.

Sponsor Phase 2b topline; no complete comparative tables. MONARCH reports incomplete fibrosis and liver-fat signals without comparator rates, key denominators or uncertainty intervals. ir.corcept.com · news release; full notes.

Sponsor clinical-development plan; initiation conditional. A second cirrhosis outcomes trial is planned conditionally for H1 2027; current noncirrhotic approval remains indication-specific. madrigalpharma.gcs-web.com · news release; full notes.

New human trial registration; no outcome result. A new FMT trial targets biological-age biomarkers, with no demonstrated healthspan or lifespan benefit. ClinicalTrials.gov · NCT07912164; full notes.

Phase 3 registry results first posted November 3; prior sponsor disclosures separate. LunAIRo adds absolute AHI effect intervals and detailed insomnia/other harms; study withdrawal and drug discontinuation are different measures. ClinicalTrials.gov · NCT05811247; full notes.

New randomized device protocol; registry fields need clarification. A new sham-controlled protocol tests sleep stimulation and cognition in MCI without establishing dementia prevention. ClinicalTrials.gov · NCT07911826; full notes.

Peer-reviewed subgroup analysis of an older randomized trial. A new subgroup paper reanalyzes an existing six-week trial; nominal subgroup findings do not establish different benefit between groups. psychiatrist.com · news release; full notes.

Sponsor enrollment milestone and forecasts. The endometrial cohort has completed enrollment, with outcomes still forecast for end-2027. ir.corcept.com · news release; full notes.

New registered prospective observational case-only protocols; no results. Two small case-only protocols assess neck lines and periorbital hollowing, with no comparative or durable-benefit results. ClinicalTrials.gov · NCT07912879; full notes.

Peer-reviewed Phase 3 full report; prior topline efficacy not newly dated. Full 52-week oral-povorcitinib trials add precise benefit intervals and uncommon harms; efficacy toplines were already known, and benefit is not a cure. Nature · article; full notes.

New randomized Phase 4 registry protocol; no results. A new 100-woman trial tests concurrent romosozumab/denosumab using hip bone density rather than fractures. ClinicalTrials.gov · NCT07909304; full notes.

Sponsor development forecast; no new efficacy result. The sponsor gives a mid-2027 DPN readout window without releasing new outcomes. investors.vrtx.com · news release; full notes.

New Phase 2b/3 registration plus dated sponsor dosing announcement. A late-stage RSV antiviral trial is now registered and sponsor dosing announced, with symptoms and hospitalization measured separately. ClinicalTrials.gov · NCT07908381; full notes.

New randomized Phase 4 protocol; no results. A new HIV switch trial studies daily oral BIC/LEN, distinct from injectable prevention. ClinicalTrials.gov · NCT07908446; full notes.

Partner-reported FDA tentative approval and supply forecast. Reported tentative approval may expand lower-cost HIV prevention in licensed countries; U.S. generic sales are not authorized by that status. wrhi.ac.za · news release; full notes.

Primary registry termination update; no clinical result. A three-participant kidney study records strategic termination, without results or evidence that safety or efficacy caused the decision. ClinicalTrials.gov · NCT06209736; full notes.

Sponsor/official conference interim data plus primary registry stage update. Early liver-fat biomarker findings are joined by a separately registered actual Phase 3 start; neither establishes clinical benefit. investor.regeneron.com · news release; full notes.

New trial registration; diagnostic performance protocol. A large AI validation protocol measures detection accuracy on existing CT scans, with no demonstrated screening-outcome benefit. ClinicalTrials.gov · NCT07911397; full notes.

New Phase 2 protocol; no results. A new trial targets fear of recurrence after early breast cancer, distinct from preventing cancer recurrence. ClinicalTrials.gov · NCT07909408; full notes.

Newly registered Phase 2 open-label study; primary immune target engagement. An open-label depression study primarily measures immune engagement; clinical benefit remains untested against depressed placebo controls. ClinicalTrials.gov · NCT07908563; full notes.

Peer-reviewed decision model; not a clinical trial. A new model favors sequential untested transfers under specific embryo-classification and cost assumptions; it is not a clinical trial. Springer · article; full notes.

New registered uncontrolled human interventional protocol. An uncontrolled enzyme-study protocol spans fat, cellulite and other aesthetic applications; no efficacy or comparative safety is established. ClinicalTrials.gov · NCT07908953; full notes.

Peer-reviewed assessor-blinded randomized split-scar human trial; abstract appraised. A 36-patient split-scar trial favors a combined prevention regimen at six months; quantitative effect and full harms tables remain gaps. PubMed · PMID 42969753; full notes.

New randomized evaluator-blinded active-controlled device-study registration. A new active-controlled cheek-filler trial measures response six months after last treatment, with no results or new U.S. approval. ClinicalTrials.gov · NCT07909421; full notes.

New retrospectively registered randomized assessor-blinded protocol; no outcomes. A retrospectively registered facial-vitiligo comparison uses the same laser background; no clinical outcomes are posted. ClinicalTrials.gov · NCT07909668; full notes.

New randomized assessor-blinded procedural protocol; no results. A new childhood-crowding trial plans long-term bite-quality and harm assessments; it has no results yet. ClinicalTrials.gov · NCT07911176; full notes.

Peer-reviewed longitudinal human prediction study. Combining environmental factors and PRS modestly improves cohort prediction; calibration and clinical utility remain unproven. Nature · article; full notes.

FDA approval, prescribing information and postmarketing requirement. FDA accelerated approval resolves the RRP action window; the adult indication, small uncontrolled efficacy subset and confirmatory requirements matter. FDA · announcement; full notes.

Peer-reviewed Phase 3 human randomized trial. ATTAIN-J adds 72-week dose-specific estimates in a Japanese obesity cohort with mixed diabetes status, with distinct population and harms limits. ATTAIN-J Phase 3 randomized publication, Lancet Diabetes & Endocrinology; full notes.

Sponsor topline result and discontinuation plan. ALTITUDE-AD missed cognitive/function endpoints despite plaque reduction; the sponsor plans to cease development. investors.acumenpharm.com · news release; full notes.

Newly posted trial-registry results; active-dose comparison without placebo. Dose-finding tables add symptoms and harms with an active-dose comparison, standard deviations and completer-analysis limits. ClinicalTrials.gov · NCT06215261; full notes.

Peer-reviewed multicentre retrospective human cohort; abstract appraised. A retrospective alopecia-areata switch cohort reports responses after baricitinib, with selection and follow-up limitations; this is distinct from pattern hair loss. PubMed · PMID 42961619; full notes.

Peer-reviewed single-centre randomized human comparison; full original methods appraised. A small single-centre comparison favors a combined acne regimen, with limitations from cointerventions, follow-up and incomplete masking. jove.com · source page; full notes.

New original registry results from a randomized controlled human trial. The per-protocol set had longer reported treatment with three-day changes; inconsistent accuracy fields and missing planned measurements limit conclusions. ClinicalTrials.gov · NCT05905224; full notes.

Sponsor-only randomized Phase 2a topline. A 119-person COPD study failed its efficacy endpoints and reported more respiratory adverse events and discontinuations, without numerical harm rates. GlobeNewswire · news release; full notes.

New Phase 3 registration. A newly registered 1,800-person COPD study measures exacerbations rather than only short-term spirometry; no results or actual first dosing. ClinicalTrials.gov · NCT07907991; full notes.

New randomized Phase 1 registry results. A 62-person dialysis study adds short-term feasibility and safety observations for empagliflozin, not evidence of improved survival or a new approved dialysis indication. ClinicalTrials.gov · NCT05614115; full notes.

New registered Phase 2 biomarker protocol; no results. A 22-person randomized trial will test whether tirzepatide changes a proteomic brain-age estimate. It cannot establish brain rejuvenation or longer life. ClinicalTrials.gov · NCT07906041; full notes.

Trial-registry update plus dated sponsor material; no efficacy results. New registry completion closes an operational gap, with enrollment and sponsor-date discrepancies unresolved. ClinicalTrials.gov · NCT06524830; full notes.

Sponsor initiation announcement plus public Phase 2 protocol; no results. A new mechanism enters controlled depression research, with primary safety testing and no benefit result yet. alkermes.gcs-web.com · news release; full notes.

Dated sponsor availability clarification. A new sponsor notice explicitly rejects commercial-availability and authorized-seller claims while formal clinical development continues. Unauthorized online sales clarification; full notes.

New randomized human-study registration; no results. A newly registered 200-woman PP405 trial specifies a controlled 24-week hair-count endpoint; recruitment and results remain pending. ClinicalTrials.gov · NCT07907783; full notes.

Peer-reviewed randomized human trial; newly recovered original October report. A small randomized COMISA trial adds insomnia and short-term breathing evidence for clinician-guided digital CBT-I. Primary source; full notes.

Sponsor study-amendment announcement and forecast. A planned GLP-1 combination expands taldefgrobep’s body-composition study; sponsor topline timing is now H2 2027, without new efficacy results. primary source; full notes.

Dated sponsor conference/webinar announcement. The first ALLO-329 autoimmune data update now has a specific November 9 date; no result is established by the invitation. ir.allogene.com · news release; full notes.

Sponsor Phase 1 report; analgesic efficacy not established. New healthy-volunteer findings support further testing, not established pain relief; Phase 2 acute-pain studies are forecast for H1 2027. investor.xenon-pharma.com · news release; full notes.

New Phase 4 protocol; nonrandomized historical comparator. A new suzetrigine hip-fracture study uses historical controls, so future comparative claims will require caution. ClinicalTrials.gov · NCT07905404; full notes.

New Phase 3 registry records; possible duplicate registration. Two new dust-mite records share one protocol ID; the participant counts cannot safely be summed. ClinicalTrials.gov · NCT07904052; full notes.

New Phase 1 registration. A small new pancoronavirus vaccine protocol will assess safety and immune breadth; it provides no evidence of broad clinical protection yet. ClinicalTrials.gov · NCT07902583; full notes.

New randomized Phase 3 registry results; prior lack-of-efficacy termination. ARTEMIS registry tables show no benefit from perioperative ravulizumab on a 90-day kidney/death composite. The trial had already been stopped for lack of efficacy in April. ClinicalTrials.gov · NCT05746559; full notes.

New registered Phase 3 protocol; no results. New EVERGREEN registration plans a 480-person JADE101 IgAN study using proteinuria at 52 weeks as its primary endpoint, with two maintenance intervals. ClinicalTrials.gov · NCT07902817; full notes.

New registered Phase 2 protocols; no results. New trials will assess one preoperative 5 mg lemborexant dose using wearable total sleep time; they do not yet establish sleep-architecture or surgical benefit. ClinicalTrials.gov · NCT07903038; full notes.

Sponsor report of randomized Phase 2 conference results. Small randomized vaccine study adds survival and harms detail, with benchmark and direct-comparison limitations. ml-eu.globenewswire.com · source page; full notes.

Dated sponsor development update; no new efficacy readout. New sponsor timing and trial initiation broaden zanzalintinib development; outcomes and approval remain pending. ir.exelixis.com · news release; full notes.

First public registry results from prematurely terminated randomized Phase 2 study. A recruitment-limited study supplies sparse safety reporting but no usable comparative efficacy estimate. ClinicalTrials.gov · NCT06341712; full notes.

Sponsor announcement of scheduled scientific presentations. Specific November sessions identify the next Alzheimer efficacy and safety evidence to appraise. biogen.gcs-web.com · news release; full notes.

Public randomized Phase 2 protocol; no results. A new oral Alzheimer program will test clinical decline over one year, with no outcomes yet. ClinicalTrials.gov · NCT07905352; full notes.

Sponsor development announcement plus older original registry. The second pivotal CBL-514 study has sponsor-announced enrollment; the registry still lags at not yet recruiting, and no Phase 3 efficacy result is available. SUPREME-02 enrollment announcement; full notes.

Peer-reviewed randomized study; primary abstract only. A 120-person randomized burn-reconstruction report describes less scarring but slower healing and poorer early graft survival; effect sizes and full harms remain inaccessible. PubMed · PMID 42954344; full notes.

Registry recruitment and actual-start update; no results. A 163-person Chinese RADIESSE follow-up study has started, adding a future delayed-safety/durability program without new comparative results. ClinicalTrials.gov · NCT07856797; full notes.

Retrospectively registered randomized human protocol; no results. A small facial-vitiligo trial compares two topical drugs on the same excimer-light background; its late registration and no-results status remain explicit. ClinicalTrials.gov · NCT07904910; full notes.

Peer-reviewed retrospective cohort; primary indexed abstract appraised. A 344-person retrospective cohort records caries after enamel reduction, but does not estimate the risk difference versus untreated teeth; surface and patient denominators remain distinct. PubMed · PMID 42958839; full notes.

Recovered sponsor-reported regulatory hearing schedule. The sponsor specifies a December 14–18 jet-lag hearing window; this is a regulatory proceeding, not approval. Primary source; full notes.

Recovered sponsor development milestone; no efficacy result. REGAL reaches its final-analysis trigger; comparative survival results are still pending. Original October 28 final-analysis-trigger release; full notes.

New randomized active-controlled protocol. A newly posted randomized knee-OA cell-therapy protocol separates clinical symptoms from MRI structure; no efficacy results yet. ClinicalTrials.gov · NCT07901790; full notes.

Phase 3 registry results. New ARNASA tables show a null two-week comparison and a nominal four-week result; efficacy and actual-treatment safety denominators differ. ClinicalTrials.gov · NCT05595642; full notes.

Open-label Phase 3 extension registry results. The long-term peanut-patch extension posts challenge and safety counts, but attrition, ongoing therapy and absent concurrent placebo prevent claims of cure. ClinicalTrials.gov · NCT03859700; full notes.

Sponsor-only Phase 3 topline; randomized active comparison. In a randomized 80-week T2D study, retatrutide lowered HbA1c by 2.2 points and weight by 19.5–20.9%, versus 1.8 points and 9.4% with Ozempic 2 mg; sponsor-only efficacy estimand, with more discontinuations at retatrutide 12 mg. Lilly · news release; full notes.

Peer-reviewed Phase 2 randomized publication and registry tables. The full acmopatide Phase 2 publication adds a modest nominal HbA1c benefit at the middle dose and weight loss in type 1 diabetes; higher-dose superiority and long-term safety are not established. DOI · 10.2337/dc26-1059; full notes.

New registered Phase 3 protocol; no results. New ENLIGHTEN-10 registration broadens eloralintide development to T2D with increased CV risk, measuring weight and HbA1c rather than major cardiovascular events. ClinicalTrials.gov · NCT07900633; full notes.

Sponsor development update; forecasts are not trial results. Viking forecasts Phase 3 extension starts in Q1 2027 and extension data in 2028, maintenance Part 2 results in 2027, and the next VK3019 steps across Q4 2026/Q1 2027. ir.vikingtherapeutics.com · source page; full notes.

New ClinicalTrials.gov results posting from a completed randomized Phase 2b study. New FORTUNA registry tables show no significant histological benefit for either AZD2693 dose versus placebo. This is a completed older trial with a new results posting, not a new treatment approval. ClinicalTrials.gov · NCT05809934; full notes.

New randomized Phase 3 registry results; safety-table limitations. The new RED-C-3132 registry results do not show prevention of first overt hepatic encephalopathy or death with rifaximin SSD 40 mg twice daily. Safety fields need clarification. ClinicalTrials.gov · NCT05297448; full notes.

New registered human protocols; no results. New small human trials will test rupatadine and roflumilast against ultrasound liver-fat measures; neither has efficacy results or an established MASH indication. ClinicalTrials.gov · NCT07900100; full notes.

Public Phase 2/3 protocol; no results. A new controlled RP program will measure visual fields and function rather than only light detection. ClinicalTrials.gov · NCT07901751; full notes.

Peer-reviewed uncontrolled cohort; full article and adverse-event table appraised. An uncontrolled 217-person IPL report adds pigment-change and other reaction counts; conflicting efficacy and ethics statements substantially limit interpretation. primary source; full notes.

Registry results. A 20-woman randomized study posts lean-mass and function measurements without between-group tests. It cannot establish a muscle-preserving advantage, equivalence, or fracture benefit. ClinicalTrials.gov · NCT05666310; full notes.

New human trial registrations. Two new early-childhood food-allergy protocols assess supervised oral immunotherapy. Challenge tolerance during treatment is separate from durable remission or cure. ClinicalTrials.gov · NCT07899359; full notes.

New Phase 2a registration and earlier sponsor announcement. The new registry clarifies FLINTLOCK’s safety/PK primary endpoints and separate Long COVID/post-vaccination cohorts. It still says not yet recruiting despite earlier sponsor initiation wording. ClinicalTrials.gov · NCT07899346; full notes.

Trial registry. New related-metabolic mechanism: a small LEAP2 infusion experiment measures food intake, without chronic weight-loss or outcome claims. ClinicalTrials.gov · NCT07897383; full notes.

Registry results with PK/PD modeling. New registry results show modeled liver-target suppression, with no placebo-controlled fibrosis or clinical-outcome evidence. ClinicalTrials.gov · NCT06104319; full notes.

Source date unknown; checked October 27. Original conference abstracts; uncontrolled extension. Original conference abstracts close an elapsed-window gap: durable proteinuria reductions, uncontrolled 76-week eGFR observations and important baseline-scarring differences. asn-online.org · source page; full notes.

Trial registry. New post-transplant prevention protocol extends the research question beyond treating established C3G/IC-MPGN; no results yet. ClinicalTrials.gov · NCT07898774; full notes.

Trial registry. New device study addresses an OSA anatomical subgroup with limited evidence; primary physiology and secondary AHI/function remain unmeasured. ClinicalTrials.gov · NCT07898618; full notes.

Trial registry. New PAP-software protocol targets residual home-treatment performance; it starts in a future estimated window and does not measure PSG architecture. ClinicalTrials.gov · NCT07898254; full notes.

Trial-registry status update; no results. The Phase 3 study completed October 23; efficacy and adverse-event results have not been posted. ClinicalTrials.gov · NCT06564818; full notes.

registry recruitment update; Phase 2 protocol. A formal verteporfin scar-prevention study has moved to recruiting; no human efficacy result or confirmed first-dose date. ClinicalTrials.gov · NCT07488988; full notes.

new randomized human-study registration; no results. New 30-person bracketless-wire versus braces protocol includes root, bone and gum outcomes, but only early alignment follow-up and no results yet. ClinicalTrials.gov · NCT07897864; full notes.

Sponsor Phase 2 topline result; newly recovered original source. A 95-person uncontrolled ovarian cohort reports response/PFS signals; no concurrent comparison establishes added survival benefit. ir.corcept.com · news release; full notes.

Peer-reviewed randomized trial; abstract appraised, complete tables inaccessible. Peer-reviewed mebufotenin data show a short-term symptom advantage with substantial adverse-event reporting. JAMA Network · article; full notes.

Phase 2 registry results. A 200-infant randomized study posts immunogenicity and safety data; stronger antibody responses do not yet establish prevention of clinical Shigella infection. ClinicalTrials.gov · NCT06663436; full notes.

Trial registry. New 3,000-person Phase 3 registry adds olatorepatide to the human obesity pipeline; doses and results remain unpublished. ClinicalTrials.gov · NCT07896265; full notes.

Randomized trial registry results. Newly posted BARI-STEP tables support semaglutide weight reduction after poor bariatric response, with attrition and selected-population limits. ClinicalTrials.gov · NCT05073835; full notes.

First trial registration plus sponsor development announcement. New human-stage lipid gene-editing entrant targets LDLR expression; registry enrollment has not started and no human LDL or CV-outcome results exist. ClinicalTrials.gov · NCT07894887; full notes.

Sponsor-hosted primary conference presentation. New procedural-burden details after positive Galleri screens; no patient-outcome benefit established. grail.com · source page; full notes.

Public human-study registry; no results. A novel human-stage screening approach is registered, but its immediate test is reproducibility, not effectiveness. ClinicalTrials.gov · NCT07894081; full notes.

FDA regulatory decision; randomized Phase 3 efficacy summary. New FDA-approved prostate-cancer use improves radiographic progression-free survival; survival followup remains important. FDA · regulatory information; full notes.

Dated sponsor forecast plus trial registry; no efficacy result. A new November forecast brings an Alzheimer clinical and safety readout closer; no efficacy data yet. investors.acumenpharm.com · news release; full notes.

Public randomized Phase 2 human protocol; no results. A new VA trial addresses depression and expectancy; its enrollment fields conflict and no outcomes exist. ClinicalTrials.gov · NCT07895134; full notes.

Sponsor human-development announcement. Credible planned human entrant: oral small-molecule amylin agonist ASC39 has an IND submission and Q4 start forecast, without verified clearance or human results. PR Newswire · news release; full notes.

Sponsor-funded primary conference poster; retrospective claims analysis. A selected claims cohort adds real-world workup information, with important verification and selection limits. grail.com · source page; full notes.

peer-reviewed placebo-controlled Phase 3 full report of an older trial. New full publication clarifies rapid, short-lived glabellar effects and adverse events from an older Phase 3 trial; no new U.S. approval. DOI · 10.1093/asj/sjag198; full notes.

New trial registration. A new T1D trial makes lean tissue its primary endpoint and separately measures strength and function; no results or confirmed actual first dosing are public. primary source; full notes.

Sponsor conference report and investigator follow-up. An interim MS CAR-T report includes a late death from septic pneumonia following persistent motor symptoms and additional immunosuppression. Small uncontrolled efficacy subsets and the unresolved enrollment pause remain separate. news.bms.com · news release; full notes.

Trial registry. Formal human records add recruiting oral and injectable ASC36 amylin studies; efficacy and durability remain unknown. ClinicalTrials.gov · NCT07893106; full notes.

Original conference abstract and sponsor report. Original pediatric abstract reports a 29.6-minute first-dose PSG sleep-time difference at 50 mg; 14-day exposure leaves long-term benefit/safety unknown. Idorsia original October 23 release; full notes.

Public randomized human protocol; no results. A new controlled human program tests digital CBT for panic disorder, without outcomes yet. ClinicalTrials.gov · NCT07892885; full notes.

new human-study registration; no results. New 90-person randomized gel study for hypertrophic scars; mechanism and doses undisclosed, with an estimated February 2027 start. ClinicalTrials.gov · NCT07891416; full notes.

peer-reviewed randomized assessor-blinded comparative human study. An assessor-blinded 120-person trial found better six-month scar scores with added PRP, at the cost of more pain; registration, masking and structural-endpoint limitations remain. Springer · article; full notes.

new observational study registration; no results. A new 300-person Chinese Sculptra cohort will collect delayed safety and appearance outcomes to two years after treatment; no comparative results yet. ClinicalTrials.gov · NCT07891767; full notes.

Dated sponsor first-patient announcement, recovered in this review. Recovered October 22 sponsor confirmation of first dosing resolves an earlier acne-trial milestone; topline remains forecast for H2 2027. GlobeNewswire · news release; full notes.

Peer-reviewed randomized Phase 3 publication; sponsor supplies component and safety tables. Final randomized VISIONARY results show a 4.5 mL/min/1.73 m²/year eGFR-slope advantage over two years and fewer composite kidney-decline/failure events. Traditional FDA approval is still a separate review. PubMed · PMID 42911185; full notes.

New Phase 3 registration. A new 6,000-person Phase 3 protocol compares combined versus separate flu/COVID vaccination in adults ≥60; primary antibody endpoints are distinct from clinical prevention. ClinicalTrials.gov · NCT07890454; full notes.

Primary ASHG conference account of prospective newborn genomic screening. Newborn sequencing uncovered actionable cardiac variants and prompted family care; clinical-outcome benefit remains unmeasured. ashg.org · news release; full notes.

Primary ASHG conference account of prospective international diagnostic study. Rapid genomes provide frequent diagnoses in infant epilepsy, with clinical benefit beyond diagnosis still to be measured. ashg.org · news release; full notes.

FDA regulatory decision; pooled single-arm confirmatory evidence. FDA confirms benefit in a narrower TMB population; the old 10–<13 threshold did not gain confirmation. FDA · regulatory information; full notes.

Public Phase 2/3 randomized protocol; no results. A substantial randomized study asks whether bispecific consolidation can replace transplant in standard-risk myeloma. ClinicalTrials.gov · NCT07887984; full notes.

Public randomized Phase 2 protocol; no results. A randomized therapeutic vaccine trial will test overall survival in molecularly selected astrocytoma. ClinicalTrials.gov · NCT07888647; full notes.

peer-reviewed randomized pilot; preliminary procedural evidence. A 30-person AGA pilot reports larger hair-density changes with a laser/serum package, but unmatched home treatments and no standard-drug comparator prevent a superiority claim. Springer · article; full notes.

new registry entry and sponsor regulatory/development announcement; no efficacy results. A new mechanism for vitiligo joins the human-study watchlist: anti-CXCL10 EB06, with no results yet; U.S. sites and Q4 2027 topline remain forecasts. ClinicalTrials.gov · NCT07889492; full notes.

Original sponsor release of randomized double-blind Phase 3 results; full peer-reviewed paper not verified as published. Adding the individualized mRNA therapy to pembrolizumab improved recurrence-free and distant-metastasis-free survival after melanoma surgery. Overall survival remains immature; the detailed release precedes the scheduled October 24 presentation. merck.com · news release; full notes.

Original investigator-institution announcement of a planned placebo comparison; no new efficacy results. KeTADiD will examine IV ketamine tolerability in older adults with major depression and mild cognitive impairment or mild dementia. December enrollment is a forecast, and registry ID, phase and sample size were not supplied. news.vumc.org · news release; full notes.

Peer-reviewed observational study. An observational osteoporosis cohort favors denosumab on strength and some later lean-mass measures, but nonrandom treatment choice and attrition limit causality; falls and fracture comparisons were not significant. primary source; full notes.

New Phase 1/2 registration. A newly registered prime-editing program targets inherited AAT deficiency across lung/liver groups. It is not yet recruiting and has no human results. primary source; full notes.

FDA label and randomized Phase 3 publication. New U.S. accelerated IgAN approval is based on lower proteinuria; confirmatory kidney-function benefit remains unproven. astrazeneca-us.com · news release; full notes.

Peer-reviewed randomized Phase 3 report; abstract appraised. New peer-reviewed OSA paper quantifies AHI reduction in obesity with and without diabetes; full harms tables remain inaccessible. PubMed · PMID 42904878; full notes.

Public randomized human protocol; no results. A prospective study will assess clinical outcomes from a package that includes pharmacogenomics and drug monitoring. ClinicalTrials.gov · NCT07885722; full notes.

Public randomized Phase 3 protocol; no results. A new randomized first-line CAR-T strategy is registered for transplant-ineligible myeloma. ClinicalTrials.gov · NCT07887672; full notes.

registry-posted human results; uncontrolled Phase 2a. First results posting for an older 12-woman cellulite study: short-term score improvement, with thigh-level denominators, injection-site reactions and no control group. ClinicalTrials.gov · NCT05632926; full notes.

Sponsor/conference disclosure; uncontrolled 26-person follow-up. The same cohort gains responder and walking-distance detail; comparative benefit and rare/long-term safety remain unresolved. ir.kyvernatx.com · news release; full notes.

New Phase 3 randomized antibiotic protocol; no results. A 324-person study compares antibiotic strategies for hospital-acquired or ventilator-associated pneumonia, with 14-day mortality primary. ClinicalTrials.gov · NCT07885891; full notes.

Independent assessment-process announcement, draft scope and published timeline; not new clinical-trial results or a regulator decision. ICER will assess the comparative effectiveness and value of investigational psilocybin therapy COMP360. Comments on scope close November 10; draft evidence is scheduled for March 16, 2027 and the public meeting for May 20. icer.org · news release; full notes.

Peer-reviewed prespecified descriptive process evaluation. Newly appraised process data explain antibiotic-guidance uptake; earlier advice is distinct from measured shorter treatment or improved survival. DOI · 10.1111/anae.70439; full notes.

FDA approval and prescribing information. The October 20 approval provides a finite-course option for a restricted hepatitis B population: 19% met the off-treatment endpoint versus none on control. Boxed liver-flare and platelet warnings, selection criteria and unverified launch matter. primary source; full notes.

Registry timing update; no results. The 150-person study now reports October 7 initiation and August 2027 completion estimates. ClinicalTrials.gov · NCT07777575; full notes.

Early-phase registry recruitment update; no first-dose confirmation. Roche’s 104-person safety/PK program is recruiting, while its start remains estimated. ClinicalTrials.gov · NCT07822334; full notes.

Sponsor-only human-administration claim; clinical outcomes undisclosed. Radical Numerics reports treatment of one patient, without disclosing response, harms or durable infection clearance. radicalnumerics.ai · source page; full notes.

New Phase 2/3 randomized active-controlled protocol; no results. The 1,806-person study tests immune-response noninferiority and safety, rather than clinical flu prevention. ClinicalTrials.gov · NCT07883928; full notes.

Sponsor-posted small, open-label, nonrandomized pharmacokinetic study. Exposure was higher in severe renal impairment, with important limitations on interpreting small-group safety counts; this was not a cardiovascular outcome or kidney-preservation trial. ClinicalTrials.gov — NCT06643377 renal-impairment results, first posted October 20, 2026; full notes.

Posted randomized phase 2 registry results; mixed coprimary outcomes, attrition and reporting inconsistencies. Total-sleep-time treatment-by-time p=.04, but wake-after-sleep-onset p=.10 and perceived-stress p=.27. Screening enrollment was 249, not 249 randomized. ClinicalTrials.gov · NCT04287062; full notes.

Primary registry status disclosure; exact hold onset unknown and no posted results. The inhaled-azacytidine lung-cancer combination is suspended to new recruitment pending modification of the monoclonal-antibody treatment. The record does not identify a toxicity cause. ClinicalTrials.gov · NCT06694454; full notes.

New Phase 1/2 human protocol; recruiting listed, actual first dosing unverified. An early Chinese study will test an on-site CAR-T manufacturing workflow. A proposed six-hour release process is a protocol claim, not demonstrated clinical throughput or better outcomes. ClinicalTrials.gov · NCT07882641; full notes.

New first-in-human Phase 1 protocol; not yet recruiting and no results. RO7821657 adds a CEACAM5-targeted T-cell engager to the pipeline. Conditional activation aims to improve selectivity, but safety and clinical benefit remain untested in the reported record. ClinicalTrials.gov · NCT07883577; full notes.

Original trial registrations, first posted October 19 and October 20; no results. NOA HYDRATION enters a 150-person randomized skin-quality study in China; MD60002 has a planned 43-person uncontrolled polynucleotide study in Italy. Neither establishes regeneration or durable lifting. ClinicalTrials.gov · NCT07880756; full notes.

New randomized procedure protocol; registered after reported start. A 60-person trial measures knee symptoms/function and imaging; both groups receive CARTISTEM. ClinicalTrials.gov · NCT07881445; full notes.

New Phase 2 randomized protocol; recruitment pending. Forty-five adults will continue suppressive ART while a repurposed oncology drug is tested for safety and virologic effects. ClinicalTrials.gov · NCT07881809; full notes.

Sponsor-entered ClinicalTrials.gov protocols; no trial results. Lilly registered two 100-week phase 3 trials: AMPLIFY-1 plans 2,115 participants without diabetes; AMPLIFY-2 plans 1,000 with type 2 diabetes. Both were not yet recruiting in the October 20 records. ClinicalTrials.gov · NCT07881432; full notes.

Dated sponsor conference announcement; no new outcome tables. Structure announced ACCESS extension and dose-ranging posters for ObesityWeek on November 15. ir.structuretx.com · news release; full notes.

Sponsor-posted results of a randomized phase 1 trial; small exploratory biomarker cohorts. Newly posted results from a 153-person phase 1 study include liver-fat and lipid changes, but all reported placebo-adjusted weight confidence intervals crossed zero and several registry fields need clarification. ClinicalTrials.gov · NCT05378893; full notes.

Sponsor presentation schedule; no new effect estimates appraised. Biogen/Sobi announced 76-week VALIANT/VALE follow-up at ASN. The October 22 adolescent slot has elapsed; the October 24 overall slot remains a scheduled follow-up. investors.biogen.com · news release; full notes.

New randomized unmasked protocol; no results or regulatory clearance. A 60-person Taipei pilot will test whether AI education added to digital brief behavioral insomnia treatment improves four-week insomnia symptoms. ClinicalTrials.gov · NCT07880561; full notes.

New sponsor-entered phase 3 protocol; no outcomes. Pfizer plans 258 adults with overweight/obesity and moderate-to-severe OSA who cannot or will not use PAP; PSG AHI at 52 weeks is primary. ClinicalTrials.gov · NCT07881757; full notes.

Primary registry registration of an observational human screening study; no results. An Italian program will use historical mammograms to reconstruct a selective third-reader strategy, measuring detection, false positives and diagnostic burden. Its alternative workflow is emulated, not prospectively assigned. ClinicalTrials.gov · NCT07879937; full notes.

Peer-reviewed multicohort human genetic association study; not an interventional screening trial. A common CD36 variant contributes substantial modeled cardiomyopathy burden in African-ancestry cohorts, but screening benefit and individual absolute risk are not established. JAMA Network · article; full notes.

FDA accelerated approval, updated prescribing information and single-arm AZUR-1 evidence. A new U.S. indication may spare some MSI-H/dMMR rectal-cancer patients surgery and chemoradiation. Long-term relapse risk remains unknown and confirmatory evidence is required. FDA · regulatory information; full notes.

First public registry results posting for an older terminated Phase 1/2 study. The older metastatic-colorectal study reports immunogenicity in 17/19 assessed patients but objective response in 1/25 treated. Development-based termination is not described as a new safety failure. ClinicalTrials.gov · NCT05589597; full notes.

First registry results disclosure from a Phase 2 study completed in2023; not a new 2026hold. A small nivolumab/IDO1-inhibitor study reports a historical toxicity-related stop and limited response data. Its external control participants are not newly randomized patients. ClinicalTrials.gov · NCT03854032; full notes.

New single-arm, open-label human device protocol; no outcome data. An Israeli study will assess deepTMS with brief trauma exposure in72 adults. It adds a diagnosis-specific program but lacks a sham comparator and cannot yet establish benefit. ClinicalTrials.gov · NCT07880340; full notes.

Sponsor Phase 3 topline, SEC-filed results slides and separate development decision. LUCIA did not demonstrate vision noninferiority despite fewer injections. EyePoint will end the pivotal wet-AMD trials before full year-two follow-up and focus on diabetic macular edema. investors.eyepoint.bio · news release; full notes.

Sponsor Phase 3 topline and October presentation; primary registry cross-check; no full peer-reviewed report. In 536 randomized men, extended-release oral minoxidil improved six-month hair counts and patient-rated coverage versus placebo. Adverse events were more frequent; this was not an active-treatment comparison. Veradermics — Study 304 sponsor topline, October 19, 2026; full notes.

Original randomized Phase4 trial registration; not yet recruiting, no results. A 118-person Pakistan study will compare clascoterone with clindamycin on shared adapalene/benzoyl-peroxide background therapy. This tests acne lesions and tolerability, not antimicrobial resistance itself. ClinicalTrials.gov · NCT07881315; full notes.

Peer-reviewed randomized controlled study; primary abstract appraised, full text inaccessible. Among 46 randomized patients, 44 completed. Heat-activated wires produced modest early alignment and pain differences, but six-month alignment rates did not significantly differ from conventional wires. PubMed · PMID 42888967; full notes.

New registry results disclosure of previously reported randomized trial. The older Phase 2b result shows a modest every-two-week benefit; the four-week regimen and companion Phase 3 primary test were negative. ClinicalTrials.gov · NCT05037929; full notes.

Primary trial-registry recruitment/start confirmation; no results. The tirzepatide-to-zenagamtide study resolves its elapsed October start estimate, while remaining a small uncontrolled tolerability study. ClinicalTrials.gov · NCT07868354; full notes.

New randomized Phase 2a human protocol; no results. A liver-targeted THRβ agonist will be tested for MRI-measured liver-fat reduction; fibrosis and clinical benefit remain separate questions. ClinicalTrials.gov · NCT07878091; full notes.

Prospective human screening protocol; no results. A Netherlands study plans to evaluate one-time breast MRI in 2,628 women aged 45, measuring cancers detected, tumor size, cost and participant experience. ClinicalTrials.gov · NCT07878377; full notes.

New randomized crossover phase 1/basic-science human protocol; no results. A planned 80-person study will measure simulated driving and behavioral impairment through 24 hours after psilocybin, compared with placebo and alcohol conditions. ClinicalTrials.gov · NCT07877987; full notes.

Registered randomized, outcome-assessor-masked phase 3 protocol in China; no controlled efficacy results. A new 146-person trial plans to compare intratympanic autologous circulating extracellular vesicles plus glucocorticoids with glucocorticoids alone in severe acute sudden sensorineural hearing loss. ClinicalTrials.gov · NCT07878559; full notes.

New original human-trial registration; no results. A planned 100-participant split-wound comparison will test silk dressing against Prineo or paper tape after abdominal surgery. NCT07878390; full notes.

Sponsor-hosted primary conference posters; observational survey substudies. Survey data document substantial initial distress and later lower anxiety; attrition and comparator gaps matter. grail.com · PDF document; full notes.

Dated sponsor launch announcement; geography-specific availability, not a new efficacy study. Takeda announced simultaneous ORZEYFUL launches in Japan and China. U.S. marketing still depends on DEA scheduling and the FDA-required labeling supplement. takeda.com · source page; full notes.

Primary ISRCTN registry status and dated editorial note; no efficacy result. The UK comparison of25mg versus5mg psilocybin for generalized anxiety was stopped October12. The registry cites sponsorship/prioritization, without establishing failure of efficacy or a safety-triggered stop. ISRCTN · ISRCTN14487299; full notes.

Registry withdrawals; no treated-patient safety or efficacy result. AFN50 and a distinct autologous CD19/BCMA study now record zero enrollment; withdrawal reasons do not establish toxicity or platform-wide failure. ClinicalTrials.gov · NCT07448298; full notes.

Registry status update; not a clinical-hold resolution. The 21-person YTB323 study records September completion; no results or verified lifting of the wider autoimmune hold follows. ClinicalTrials.gov · NCT05798117; full notes.

Phase 3 registration; not yet recruiting. A 2,136-person trial will test ensifentrine on top of maintenance inhalers for moderate or severe COPD exacerbations. ClinicalTrials.gov · NCT07874815; full notes.

New registry results disclosure of previously reported randomized trial. The older positive trial gains detailed efficacy and safety tables, without reversing its companion trial failure or program discontinuation. ClinicalTrials.gov · NCT04701983; full notes.

New Phase 1 randomized human protocol; no results. PF-08656795/MET-815i adds a 150-person dose-escalation protocol focused on safety and exposure, rather than a new weight-loss result. ClinicalTrials.gov · NCT07876518; full notes.

New randomized behavioral-treatment protocol; no results. The 140-person cancer-survivor trial measures insomnia severity/remission and follows durability, fatigue and quality of life. ClinicalTrials.gov · NCT07876661; full notes.

Investigator announcement of an actual development milestone, with live phase 2/3 protocol; no efficacy result. API-2 is testing donanemab, nivagacetor and their combination in PSEN1 E280A carriers. The registered primary outcomes concern amyloid removal and maintenance, so first randomization does not demonstrate dementia prevention. GlobeNewswire · news release; full notes.

Official UK safety-communication action following expert and patient review; not a new treatment trial or a new U.S. warning. UK leaflets will make suicidal-thought/behavior warnings more prominent and name post-SSRI sexual dysfunction explicitly for selected medicines. The change clarifies known risks; it does not supply a new reliable incidence estimate. gov.uk · news release; full notes.

Peer-reviewed single-arm phase 2 follow-up; results previously presented in conference form. Long-term survival after perioperative nivolumab/ipilimumab was encouraging, but the authors found no clear survival improvement over outcomes reported with surgery alone in other studies. JAMA Network · article; full notes.

Registered prospective implementation pilot; no clinical-benefit results. Columbia registered a 55-person pilot of primary-care decision support for hereditary breast/ovarian cancer testing, with an actual September 1 study start. ClinicalTrials.gov · NCT07876349; full notes.

FDA indication expansion based on extrapolation from prior CIS-containing trial evidence. Anktiva’s indication now includes BCG-unresponsive papillary-only disease. FDA explicitly extrapolated from related CIS disease rather than announcing a new randomized papillary-only result. FDA · regulatory information; full notes.

Peer-reviewed randomized sham-controlled trial; primary abstract and publisher page appraised, full text inaccessible. In 204 people already receiving first-line treatment, eight-week investigator-rated clear/almost-clear responses were 58/102 with active versus 36/102 with sham acupressure. Single-center findings need replication. PubMed · PMID 42873508; full notes.

New Phase 1 trial registration; recruitment pending. BMS-986553 plans a 60-person safety-first study in refractory autoimmune disease; no patients or results are verified. ClinicalTrials.gov · NCT07873931; full notes.

Dated sponsor development announcement reconciled with October 16 trial records; no efficacy readout. SUNRISE advances beyond registration, while both live protocols still list recruitment pending and November starts. A maintenance-dosing wording error is explicitly corrected. ir.vikingtherapeutics.com · source page; full notes.

Sponsor-reported initiation milestone plus original Phase 2/3 registry; no new efficacy result. Pelage confirms first dosing in its large pattern-hair-loss trial and forecasts a separate women's Phase 2 study by year-end. Pelage October 14 AWAKEN first-dose announcement; full notes.

Peer-reviewed retrospective single-centre case-note review, n=38; uncontrolled and selected. A complex insomnia clinic cohort found sustained benefit in 21/38, but 9/38 stopped because of adverse effects; one patient had suicidal ideation that recurred on rechallenge. cambridge.org · article; full notes.

Peer-reviewed randomized implementation trial; self-reported genetic-testing uptake, not cancer outcomes. Digital education improved six-month testing uptake; coaching showed a later secondary benefit. Most eligible participants still did not test, and health benefit from screening was not measured. JAMA Network · article; full notes.

Sponsor-reported randomized Phase 2/3 topline result, with numerical tables undisclosed. Adding the HPV16-targeted mRNA immunotherapy to pembrolizumab did not significantly improve progression-free survival. The prespecified overall-survival primary test remains pending. biontech.com · news release; full notes.

Trial-registry update. Forazapadin (SAT-3247) adds a planned randomized trial in inherited FSHD, measuring muscle force as well as safety. This is separate from GLP-1 muscle preservation; recruitment has not begun. ClinicalTrials.gov · NCT07872306; full notes.

Trial-registry update. A randomized osteoporosis study now records actual primary completion. It tests adding abaloparatide to ongoing denosumab using bone-density outcomes; fracture benefit is not established. ClinicalTrials.gov · NCT04467983; full notes.

Trial-registry update. SUPRA-COPD plans a randomized test of urolithin A added to pulmonary rehabilitation, with exercise endurance primary. Strength and lean mass are separate secondary outcomes; there is no efficacy result. ClinicalTrials.gov · NCT07871357; full notes.

Trial-registry update. A newly registered inhaled-cell study in COPD has no randomized comparator or results. Safety and clinically significant changes are primary; registry listing does not validate lung regeneration. ClinicalTrials.gov · NCT07871890; full notes.

Trial-registry update. A 16,390-person randomized shingles-vaccine trial will directly test cardiovascular events in adults with established disease or multiple risk factors. It is not yet recruiting and does not establish cardiovascular prevention benefit. ClinicalTrials.gov · NCT07872046; full notes.

New Phase 3 human-trial registration; not yet recruiting. Amgen plans 230 adults in an open-label study of successful home self-injection, rather than a comparative weight-loss result. ClinicalTrials.gov · NCT07871409; full notes.

Newly public Phase2 human-study registration; completed earlier, no posted results. A 31-person eight-week combination pilot is now registered; it cannot establish longevity or isolate the shared investigational supplements. ClinicalTrials.gov · NCT07871799; full notes.

Primary trial-registry timing revision; no new lipid or outcome result. The previous September 2026 completion window is superseded by July 2027; the study still primarily assesses adverse events. ClinicalTrials.gov · NCT07223658; full notes.

New human device-study registration; retrospective, no posted results. BELL-001 studied immediate EEG/heart responses in 72 adults; this is not evidence of insomnia remission or restored sleep architecture. ClinicalTrials.gov · NCT07872007; full notes.

New Phase1/2 human-trial registration; earlier actual start, noresults. A 20-person immune-directed pilot tests sleepiness/cataplexy in refractory NT1; it does not establish disease reversal or comparative efficacy. ClinicalTrials.gov · NCT07871006; full notes.

New nonrandomized feasibility-study registration; noresults. A 70-person study will test an ICU day/night care package; REM/N3 measurements are secondary, not proven benefit. ClinicalTrials.gov · NCT07869901; full notes.

New formal human device-study registration; no results. SOARA will test an investigational ovarian blood screen in average-risk postmenopausal women and track invasive follow-up burden. ClinicalTrials.gov · NCT07872644; full notes.

New registration of an ongoing prospective case-control study; no results. A urine VOC biosensor study in never-smokers with existing lung nodules tests diagnostic accuracy rather than population-screening benefit. ClinicalTrials.gov · NCT07871656; full notes.

New formal phase 1/2a trial registration; explicitly not yet authorized to begin. IBO-CARE plans ibogaine versus extended-release naltrexone in OUD; its registry explicitly says the IND has not been filed. ClinicalTrials.gov · NCT07871877; full notes.

New phase 3 randomized human trial registration; no result. Trastuzumab brengitecan will be compared with platinum chemotherapy after checkpoint-based therapy in metastatic urothelial cancer. ClinicalTrials.gov · NCT07869836; full notes.

New phase 2a human trial registration; no result. LUTEON ATLAS plans two lutetium 177 girentuximab regimens in advanced CAIX-expressing clear-cell kidney cancer. ClinicalTrials.gov · NCT07870746; full notes.